Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 3/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 3/20 | 1.00 |
| ▸ | SCD5 | Q86SK9 | 16/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | SCD | O00767 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784133 | 1.00 | CYP2C8 (1.00) | CYP2C8CYP2B6SCD5CYP2C9CYP2C19 | |
| SCHEMBL21523623 | 0.91 | SCD5 (1.00) | CYP2C8CYP2B6SCD5CYP2C9CYP2C19 | |
| SCHEMBL22619737 | 0.87 | CYP2C8 (0.83) | CYP2C8CYP2B6SCD5CYP2C9CYP2C19 | |
| SCHEMBL21523801 | 0.86 | SCD5 (1.00) | CYP2C8CYP2B6SCD5SCDALDH1A1 | |
| SCHEMBL21523680 | 0.86 | SCD5 (1.00) | CYP2C8CYP2B6SCD5SCDALDH1A1 | |
| SCHEMBL21523700 | 0.86 | SCD5 (1.00) | CYP2C8CYP2B6SCD5SCDALDH1A1 | |
| SCHEMBL22619879 | 0.86 | SCD5 (0.87) | CYP2C8CYP2B6SCD5CYP2C9CYP2C19 | |
| SCHEMBL22619895 | 0.86 | CYP2C8 (0.75) | CYP2C8CYP2B6SCD5CYP2C9CYP2C19 | |
| SCHEMBL22619866 | 0.86 | CYP2C8 (0.75) | CYP2C8CYP2B6SCD5CYP2C9CYP2C19 | |
| SCHEMBL22619686 | 0.85 | CYP2C8 (0.75) | CYP2C8CYP2B6SCD5CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12226478-B2 | Method of treating, reducing, or alleviating a medical condition in a patient | PEYMAN GHOLAM A (US) | 2025-02-18 | — | — | US | claimed |
| US-20240301417-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC LIVER DISEASE AND HEPATOCELLULAR CARCINOMA | Sanford Burnham Prebys Medical Discovery Institute | 2024-09-12 | — | — | US | claimed |
| US-20230338520-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2023-10-26 | — | — | US | claimed |
| WO-2022266232-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC LIVER DISEASE AND HEPATOCELLULAR CARCINOMA | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022177402-A1 | ATF6 AS TARGET PROTEIN FOR DIAGNOSING AND TREATING TUMOR | (주)이노셀젠 | 2022-08-25 | — | — | WO | claimed |
| US-20220202933-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2022-06-30 | — | — | US | claimed |
| EP-4041727-B1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ALTOS LABS, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| WO-2025107285-A1 | METHOD FOR ISOLATING AND PURIFYING PEROXISOMES | 上海科技大学 | 2025-05-30 | — | — | WO | disclosed |
| CN-120040599-A | Method for separating and purifying peroxisome | 上海科技大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20250161334-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119925343-A | Squamocin new application | 云帆医学科技(广州)有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119823112-A | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2022177402-A1 | ATF6 AS TARGET PROTEIN FOR DIAGNOSING AND TREATING TUMOR | (주)이노셀젠 | 2022-08-25 | — | — | WO | disclosed |
| EP-4041728-A1 | ATF6 MODULATORS AND USES THEREOF | Praxis Biotech LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220202933-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2022123836-A1 | EYEDROPS FOR INHIBITING MYOPIA PROGRESSION IN CHILDREN AND SCREENING METHOD FOR INHIBITOR OF MYOPIA PROGRESSION IN CHILDREN | 株式会社坪田ラボ | 2022-06-16 | — | — | WO | disclosed |
| WO-2022123837-A1 | EYEDROPS FOR TREATING SCLERAL THINNING AND SCREENING METHOD FOR THERAPEUTIC AGENT OF SCLERAL THINNING | 株式会社坪田ラボ | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125988-A1 | DEGRADING PKCBβ1 TO TREAT CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022120055-A1 | METHODS FOR TREATING AUTOIMMUNE DISEASES | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | CYP2C8 4591/4885CYP2B6 4047/4885SCD5 2906/4885 |
| US-20240301417-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC LIVER DISEASE AND HEPATOCELLULAR CARCINOMA | ATF4, ATF1, XBP1 | CYP2C8 4433/4885CYP2B6 4518/4885SCD5 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.